NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free BLUE Stock Alerts $1.03 -0.02 (-1.90%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.02▼$1.0650-Day Range$0.89▼$1.4652-Week Range$0.85▼$5.53Volume1.86 million shsAverage Volume7.29 million shsMarket Capitalization$112.62 millionP/E RatioN/ADividend YieldN/APrice Target$5.74 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside457.7% Upside$5.74 Price TargetShort InterestHealthy29.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.02Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.72) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector559th out of 914 stocksBiological Products, Except Diagnostic Industry85th out of 153 stocks 3.1 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days.Read more about bluebird bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted29.14% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bluebird bio has recently decreased by 2.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 1.7 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for bluebird bio this week, compared to 6 articles on an average week.Search InterestOnly 23 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about bluebird bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($1.72) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesMay 17 at 5:32 PM | businesswire.comBLUE INVESTOR ALERT: Kirby McInerney LLP Notifies bluebird bio, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitMay 16 at 4:45 PM | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 16 at 9:22 AM | fool.comIs Bluebird Bio Stock a Buy?May 15, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmMay 15, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming DeadlineMay 14, 2024 | prnewswire.comROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUEMay 14, 2024 | prnewswire.comClass Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law FirmMay 13, 2024 | businesswire.comBLUE INVESTOR ALERT: Kirby McInerney LLP Notifies bluebird bio, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitMay 13, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 13, 2024 | prnewswire.comShareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMay 11, 2024 | seekingalpha.combluebird bio, Inc. (BLUE) Q1 2024 Earnings Call TranscriptMay 11, 2024 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from AnalystsMay 10, 2024 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.combluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...May 9, 2024 | msn.combluebird bio reports Q1 resultsMay 9, 2024 | finance.yahoo.combluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceMay 8, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 8, 2024 | prnewswire.comMay 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BLUEMay 7, 2024 | prnewswire.comROSEN, A LEADING NATIONAL FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUEMay 7, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmMay 7, 2024 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio, Inc. Lawsuit - BLUEMay 6, 2024 | bizjournals.comFirst sickle cell patient begins bluebird gene therapy treatmentMay 6, 2024 | businesswire.combluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor EventsMay 6, 2024 | businesswire.combluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene TherapyMay 6, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming DeadlineSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$5.74 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+457.7%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-419.64% Pretax Margin-419.50% Return on Equity-34.32% Return on Assets-14.44% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.42 Sales & Book Value Annual Sales$3.60 million Price / Sales31.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.43Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$112.62 million OptionableOptionable Beta0.82 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsSangamo TherapeuticsNASDAQ:SGMODBV TechnologiesNASDAQ:DBVTBioAtlaNASDAQ:BCABaTyr PharmaNASDAQ:LIFEMolecular PartnersNASDAQ:MOLNView All CompetitorsInsiders & InstitutionsBayesian Capital Management LPBought 40,443 shares on 5/16/2024Ownership: 0.037%Price T Rowe Associates Inc. MDBought 29,113 shares on 5/15/2024Ownership: 0.050%American International Group Inc.Bought 41,177 shares on 5/14/2024Ownership: 0.086%Vanguard Group Inc.Bought 1,723,081 shares on 5/10/2024Ownership: 9.602%SG Americas Securities LLCBought 65,710 shares on 5/7/2024Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price target for 2024? 11 Wall Street analysts have issued 1-year price targets for bluebird bio's shares. Their BLUE share price targets range from $1.02 to $13.00. On average, they predict the company's stock price to reach $5.74 in the next twelve months. This suggests a possible upside of 457.7% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2024? bluebird bio's stock was trading at $1.38 on January 1st, 2024. Since then, BLUE shares have decreased by 25.4% and is now trading at $1.03. View the best growth stocks for 2024 here. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.03. The biotechnology company earned $12.40 million during the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative trailing twelve-month return on equity of 34.32% and a negative net margin of 419.64%. The firm's revenue for the quarter was up 17364.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.92) EPS. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM). What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.60%), Mirae Asset Global Investments Co. Ltd. (0.30%), BNP Paribas Financial Markets (0.09%), American International Group Inc. (0.09%), SG Americas Securities LLC (0.07%) and Price T Rowe Associates Inc. MD (0.05%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLUE) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.